GARDEN CITY, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, will release its third quarter 2026 financial results before market open on Thursday, November 5, 2026. The Company will host a conference call to discuss the results on the same day at 11:00 a.m. Eastern Time. The Company will also host an Investor Day on Tuesday, December 1, 2026, at the Nasdaq MarketSite in New York City.

Third Quarter 2026 Conference Call

Investors and analysts may access the live conference call by dialing 1-833-862-0366 (USA) or 1-412-634-6210 (International). In addition, a live webcast of the conference call will be accessible through the investor relations website here.

For those who cannot listen to the live broadcast, an audio replay of the webcast will be available on the Company’s investor relations website at https://lifetimebrands.gcs-web.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International) and entering access code 10212812. 

Investor Day

The Company will host an Investor Day on Tuesday, December 1, 2026, at the Nasdaq MarketSite in New York City, from 11:00 a.m. to 2:00 p.m. Eastern Time. Members of the Company’s senior leadership team will provide an overview of the business, followed by a panel discussion with the Company’s Division Presidents and a question-and-answer session. In-person attendees will also see product displays and demonstrations. Investors and analysts interested in attending in person should RSVP to LCUT@mzgroup.us.

About Lifetime Brands, Inc.

Lifetime Brands is a leading global designer, developer and marketer of a broad range of branded consumer products used in the home. The Company markets its products under well-known kitchenware brands, including Farberware®, KitchenAid®, Sabatier®, Amco Houseworks®, Chef’n®, Chicago™ Metallic, Copco®, Fred® & Friends, Houdini™, KitchenCraft®, Kamenstein®, La Cafetière®, MasterClass®, Misto®, Swing-A-Way®, Taylor® Kitchen, Rabbit®, and Dolly®; respected tableware and giftware brands, including Mikasa®, Pfaltzgraff®, Fitz and Floyd®, Empire Silver™, Gorham®, International® Silver, Towle® Silversmiths, Wallace®, Wilton Armetale®, V&A®, Royal Botanic Gardens Kew®, Year & Day®, Dolly®, Royal Leerdam®, and ONIS®; and valued home solutions brands, including BUILT NY®, S’well®, Taylor® Bath, Taylor® Kitchen, Taylor® Weather, Elements®, Planet Box®, and Dolly®. The Company also provides exclusive private label products to leading retailers worldwide.

The Company’s corporate website is www.lifetimebrands.com.

Contacts:

Lifetime Brands, Inc.
Laurence Winoker, Chief Financial Officer
516-203-3590
investor.relations@lifetimebrands.com

or

MZ North America
Shannon Devine
Main: 203-741-8811
LCUT@mzgroup.us

IRVING, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Quest Resource Holding Corporation (Nasdaq: QRHC) (“Quest” or the “Company”), a national leader in environmental waste and recycling services, today announced that it will release results for its third quarter ended September 30, 2026, on Thursday, November 5, 2026, after market close.

Management will host a conference call that same day at 5:00 PM ET to review the Company’s financial results and business outlook. Investors interested in participating in the live call can dial 1-877-270-2148 or 1-412-371-6060 (International). Investors can also access the call online through a listen-only webcast on the investor relations section of Quest’s website at http://investors.qrhc.com/.

The webcast, which may include forward-looking information, will be archived on the Quest investor relations website for at least 90 days and a telephonic playback of the conference call will be available by calling 1-855-669-9658 or 1-412-317-0088 (International). The replay access code is 2229290. The telephonic playback will be available approximately three hours after the conference ends and will be available through November 12, 2026.

About Quest Resource Holding Corporation
Quest is a national provider of waste and recycling services that empower larger businesses to excel in achieving their environmental and sustainability goals and responsibilities. Quest delivers focused expertise across multiple industry sectors to build single-source, customer-specific solutions that generate quantifiable business and sustainability results. Addressing a wide variety of waste streams and recyclables, Quest provides information and data that tracks and reports the environmental results of Quest’s services, gives actionable data to improve business operations, and enables Quest’s customers to excel in their business and sustainability responsibilities. For more information, visit https://questrmg.com/.

Investor Relations Contact
Alpha IR Group
Nick Nelson or Chris Hodges
QRHC@alpha-ir.com
312-445-2870

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — Carlyle Credit Income Fund (“we,” “us,” “our,” “CCIF” or the “Fund”) (NYSE: CCIF) announced today that it will release financial results after market close on Wednesday, November 18, 2026, for its fourth quarter and full year 2026. CCIF will host a conference call at 10:00 a.m. EST on Thursday, November 19, 2026, to discuss the results.

The conference call will be available via public webcast via a link on Carlyle Credit Income Fund’s website at www.carlylecreditincomefund.com and will also be available on the website soon after the call’s completion.

About Carlyle Credit Income Fund

Carlyle Credit Income Fund (NYSE: CCIF) is an externally managed closed-end fund focused on investing in primarily equity and junior debt tranches of collateralized loan obligations (“CLOs”). The CLOs are collateralized by a portfolio consisting primarily of U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors. CCIF is externally managed by Carlyle Global Credit Investment Management L.L.C. (“CGCIM”), an SEC-registered investment adviser and wholly owned subsidiary of Carlyle. CCIF draws upon the significant scale and resources of Carlyle as one of the world’s largest CLO managers.

Web: www.carlylecreditincomefund.com 

About Carlyle   

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $485 billion of assets under management as of June 30, 2026, Carlyle’s purpose is to connect people, ideas, and capital to fuel growth for companies and performance for investors. Carlyle employs more than 2,500 people in 28 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and on LinkedIn at The Carlyle Group.

Contacts:

Investors: Media:
Joseph Castilla Max Berger
+1 (866) 277-8243
investorrelations@carlylecreditincomefund.com 
+1 (917) 533-4374
Max.Berger@carlyle.com 

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia

Highlights

  • Collaboration aims to accelerate precision oncology research in Australia
  • Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program
  • Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials

DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening and trial matching organization, today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico’s precision oncology network with Fortrea’s scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment to expand access to biomarker-driven oncology research globally.

Through this initiative, Omico will support Fortrea’s clients in their oncology drug development needs by providing access to patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways in Australia, a key country both for early and late phase Oncology clinical research activities. The collaboration will combine Fortrea’s oncology drug development experience with Omico’s flagship Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, the largest cancer genomics initiative in Australia. PrOSPeCT is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies.

“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible,” said Oren Cohen, M.D., Chief Medical Officer at Fortrea. “Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”

Omico has built one of Australia’s most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. Omico has reported more than 23,000 consented patients within its clinic-genomic databases and has received referrals from more than 1,600 clinicians across Australia.

“Australia is well positioned to support global biomarker-driven clinical trials, through Omico’s established national precision oncology research infrastructure, expertise and networks,” said Professor David Thomas, Chief Science and Strategy Officer at Omico. “By combining our national data and trial matching capabilities with Fortrea’s global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.”

Fortrea’s oncology expertise is underpinned by thousands of operational professionals and supported by more than 50 oncology physicians on staff. This collaboration comes at a time when modern oncology drug development has accelerated the focus on precision medicine, biomarker-driven development and targeted patient identification. Working together, Fortrea and Omico can offer more efficient site selection and the ability to match patients with appropriate studies tied to their unique genomic data, enabling more people to participate in studies tailored to their specific condition in Australia.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn and X and Bluesky.

About Omico
Omico is an independent, national, not-for-profit research organisation changing the way we fight cancer. We work to improve outcomes for Australians with cancer by providing equitable access to precision oncology and translating scientific advances into clinical care and research, and generating the evidence needed to inform health policy and system reform. Working with Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government, we are accelerating molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence.

About PrOSPeCT
PrOSPeCT is Australia’s largest precision oncology initiative. Delivered by Omico and a national network of healthcare, research and industry partners, it provides eligible Australians with access to molecular profiling and matching to biomarker-led clinical trials and therapies (at no cost to the patient), while generating clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy.

Fortrea Contacts:
Galen Wilson (Media) – 703-298-0802, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com

Omico Contact:
Kym Bramich (Communications) – +61 414 795 087, k.bramich@omico.org.au

– Record of Over $300 Million of Investment Activity Completed and Under-Contract Year-to-Date –
– 2026 AFFO per Diluted Share Guidance Increased to $2.20 – $2.22 –

WINTER PARK, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company” or “PINE”), an owner and operator of single tenant net leased commercial income properties, today announced its operating results and earnings for the three and nine months ended September 30, 2026.

Third Quarter 2026 Highlights

Operating results for the three and nine months ended September 30, 2026 and 2025 (dollars in thousands, except per share data):

                         
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026   2025     2026   2025  
Total Revenues   $ 20,460   $ 14,563     $ 58,868   $ 43,632  
Net Income (Loss) Attributable to Common Stockholders   $ 3,443   $ (1,310 )   $ 7,510   $ (4,130 )
Net Income (Loss) per Diluted Share Attributable to Common Stockholders   $ 0.18   $ (0.09 )   $ 0.42   $ (0.29 )
FFO Attributable to Common Stockholders (1)   $ 10,356   $ 7,135     $ 29,704   $ 20,832  
FFO Attributable to Common Stockholders per Diluted Share (1)   $ 0.55   $ 0.46     $ 1.65   $ 1.34  
AFFO Attributable to Common Stockholders (1)   $ 10,423   $ 7,128     $ 29,886   $ 20,909  
AFFO Attributable to Common Stockholders per Diluted Share (1)   $ 0.55   $ 0.46     $ 1.66   $ 1.34  

____________

(1)  See the “Non-GAAP Financial Measures” section and tables at the end of this press release for a discussion and reconciliation of Net Income (Loss) to non-GAAP financial measures.

“We continued to execute on our growth strategy in the third quarter, investing nearly $41 million at an attractive weighted average initial cash yield of 8.5%,” said John P. Albright, President and Chief Executive Officer of Alpine Income Property Trust. “Including our pending $117.3 million portfolio acquisition, our closed and under-contract investment activity year-to-date exceeds $300 million, a Company record that surpasses our full-year 2025 total of $278 million. Given this strong investment activity and the continued performance of our portfolio we are raising our full-year 2026 guidance.”

Investment Activity

Investments for the three and nine months ended September 30, 2026 (dollars in thousands):

                         
    Three Months Ended
September 30, 2026
  Nine Months Ended
September 30, 2026
    Number of
Investments
  Amount   Number of
Investments
  Amount
Properties (1)     3   $ 39,210       7   $ 85,785  
Commercial Loan Originations     1     1,720       5     105,650  
Total Investments     4   $ 40,930       12   $ 191,435  
                         
Properties – Weighted Average Initial Cash Cap Rate           8.5 %           8.0 %
Commercial Loans – Weighted Average Initial Coupon Rate (2)           10.0 %           13.0 %
Total Investments – Weighted Average Initial Yield           8.5 %           10.8 %
Properties – Weighted Average Remaining Lease Term at Time of Acquisition     4.3 years     13.4 years

____________

(1) The nine months ended September 30, 2026 investments include $26.3 million of property acquisitions that are accounted for as financing arrangements for GAAP purposes and are included in the Sale-Leaseback and Sales-Type Lease Properties, hereinafter defined.
(2) Includes paid-in-kind (“PIK”) interest coupon rate.

Pending Portfolio Acquisition and New Debt Financing

On October 9, 2026, the Company announced an agreement to acquire a 13-property industrial portfolio for $117.3 million, or $63 per square foot. The portfolio totals approximately 1.9 million square feet across 11 states and is 100% leased to nine tenants under absolute triple-net leases with annual rent escalations. The leases have a weighted average remaining lease term of 10.2 years, with no lease expirations before late 2031. The acquisition is expected to close in the fourth quarter of 2026, subject to customary closing conditions.

Subsequent to quarter end, the Company received bank commitments for a new $100 million four-year term loan and a $75 million increase in commitments under its revolving credit facility, to $325 million from $250 million. The new financing will increase the Company’s potential liquidity by $175 million, providing additional capacity to fund pending and future acquisitions.The new financing is expected to close in late October 2026, and the term loan proceeds will be used to repay outstanding revolving credit facility borrowings.

Disposition Activity

Dispositions for the three and nine months ended September 30, 2026 (dollars in thousands):

                         
    Three Months Ended
September 30, 2026
  Nine Months Ended
September 30, 2026
    Number of
Investments
  Amount   Number of
Investments
  Amount
Properties     —   $ —       3   $ 5,816  
Properties (Vacant)     1     410       1     410  
Commercial Loans     —     —       1     10,763  
Total Dispositions     1   $ 410       5   $ 16,989  
                         
Properties – Weighted Average Exit Cash Cap Rate           — %           7.4 %
Commercial Loans – Weighted Average Cash Yield           — %           10.0 %
Total Dispositions – Weighted Average Cash Yield           — %           9.1 %

Investments

The Company’s property and commercial loan portfolios consisted of the following as of September 30, 2026:

     
Property Portfolio    
Number of Properties   130  
Square Feet   4.8 million  
Annualized Base Rent (ABR) (1)   $53.9 million  
Weighted Average Remaining Lease Term   8.7 years  
States where Properties are Located   31  
Industries   25  
Occupancy   99.6 %
     
% of ABR Attributable to Investment Grade Rated Tenants   56 %
% of ABR Attributable to Credit Rated Tenants   68 %
% of ABR Attributable to Sale-Leaseback and Sales-Type Lease Properties (2)   12 %
     
Commercial Loan Portfolio (3)    
Number of Commercial Loans   11  
Outstanding Face Amount (4)   $160.1 million  
Weighted Average Coupon Rate (5)   13.4 %
Weighted Average Remaining Term   1.4 years  
Unfunded Commitment Amount   $75.5 million  

____________

(1) ABR represents annualized in-place straight-line base rent pursuant to GAAP. Annualized in-place cash base rent totaled $51.8 million.
(2) The Company owns four single-tenant income properties which were acquired through sale-leaseback transactions that include tenant repurchase options and one single-tenant income property which qualifies as a sales-type lease (collectively, the “Sale-Leaseback and Sales-Type Lease Properties”). These Sale-Leaseback and Sales-Type Lease Properties are accounted for as financing arrangements for GAAP purposes. However, as they constitute real estate assets for both legal and tax purposes, we include them for purposes of describing our property portfolio, including for tenant, industry, and state concentrations and exclude them for purposes of describing our commercial loan portfolio. The Sale-Leaseback and Sales-Type Lease Properties represent 10.0% of annualized in-place cash base rent.
(3) See Supplemental Disclosure on Commercial Loans and Investments on page 14 of this press release.
(4) Net of $18.5 million A-1 Participation and $57.2 million of financing related to Sale-Leaseback and Sales-Type Lease Properties.
(5) Includes PIK interest coupon rate.

The Company’s property portfolio included the following top tenants that represent 2.0% or greater of the Company’s total ABR as of September 30, 2026:

         
Tenant   Credit Rating   % of ABR
Lowe’s   BBB+ / Baa1   14 %
Dick’s Sporting Goods   BBB / Baa2   10 %
Beachside Hospitality Group   NR / NR   7 %
Walmart   AA / Aa2   6 %
Best Buy   BBB+ / A3   6 %
Alamo Drafthouse   A+ / A2   5 %
Dollar General   BBB / Baa3   4 %
Family Dollar   NR / NR   4 %
GermFree Laboratories   NR / NR   4 %
Walgreens   NR / NR   3 %
At Home   NR / NR   3 %
Bass Pro Shops   BB- / Ba3   3 %
BJ’s Wholesale Club   BB+ / Ba1   2 %
Academy Sports   BB+ / Ba2   2 %
Dollar Tree   BBB / Baa2   2 %
TJX Companies   A / A2   2 %
Aspen Retail   NR / NR   2 %
Other       21 %
Total       100 %

The Company’s property portfolio consisted of the following top industries that represent 2.0% or greater of the Company’s total ABR as of September 30, 2026:

     
Industry   % of ABR
Home Improvement   16 %
Sporting Goods   15 %
Casual Dining   10 %
Dollar Stores   10 %
Entertainment   7 %
Grocery   7 %
Consumer Electronics   6 %
Home Furnishings   6 %
Pharmacy   4 %
Off-Price Retail   4 %
Technology, Media & Life Sciences   4 %
Wholesale Club   2 %
Other   9 %
   Total   100 %

The Company’s property portfolio included properties in the following top states that represent 2.0% or greater of the Company’s total ABR as of September 30, 2026:

     
State   % of ABR
Florida   11 %
Texas   10 %
North Carolina   9 %
New Jersey   8 %
Colorado   7 %
Virginia   6 %
New York   6 %
Michigan   6 %
Illinois   5 %
Georgia   3 %
Ohio   3 %
Minnesota   3 %
West Virginia   3 %
Tennessee   3 %
Wisconsin   2 %
Kansas   2 %
Louisiana   2 %
Oklahoma   2 %
Other   9 %
   Total   100 %

Balance Sheet and Capital Markets

     
(Dollars in table in thousands) As of September 30, 2026
Leverage    
Net Debt / Total Enterprise Value   49.5 %
Net Debt / Pro Forma Adjusted EBITDA   6.5x  
Fixed Charge Coverage Ratio   3.1x  
     
Liquidity    
Available Capacity Under Revolving Credit Facility $ 51,500  
Cash and Cash Equivalents   11,722  
Total Liquidity $ 63,222  

As of September 30, 2026, the Company had $198.5 million outstanding under its Revolving Credit Facility, which had total commitments of $250.0 million. Borrowing availability under the Revolving Credit Facility is based on unencumbered asset value, as defined in the underlying credit agreement, and as of September 30, 2026, the Company had $51.5 million of additional borrowing availability. As discussed above, subsequent to quarter end, the Company received bank commitments for $175.0 million of new financing, consisting of a $100.0 million term loan and a $75.0 million increase in Revolving Credit Facility commitments, which is expected to close in late October 2026 and increases potential liquidity by $175.0 million.

During the three months ended September 30, 2026, the Company issued 335,457 common shares under its common stock ATM offering program at a weighted average gross price of $20.01 per share, for total net proceeds of $6.6 million. During the three months ended September 30, 2026, the Company issued 63,879 preferred shares under its Series A Preferred Stock ATM offering program at a weighted average gross price of $25.22 per share, for total net proceeds of $1.6 million.

During the nine months ended September 30, 2026, the Company issued 3,136,532 common shares under its common stock ATM offering program at a weighted average gross price of $19.38 per share, for total net proceeds of $59.9 million. During the nine months ended September 30, 2026, the Company issued 406,419 preferred shares under its Series A Preferred Stock ATM offering program at a weighted average gross price of $25.18 per share, for total net proceeds of $10.0 million.

The Company’s long-term debt as of September 30, 2026 (dollars in thousands):

                   
    As of September 30, 2026
    Face Value Debt   Stated Interest Rate   Wtd. Avg. Rate   Maturity Date
Revolving Credit Facility (1)   $ 198,500   SOFR +
[1.25% – 2.20%]
  4.96 %   February 2030
2029 Term Loan (2)     100,000   SOFR +
[1.25% – 1.90%]
  4.66 %   February 2029
2031 Term Loan (3)     100,000   SOFR +
[1.25% – 1.90%]
  3.35 %   February 2031
Total Debt/Weighted-Average Rate   $ 398,500       4.48 %    

____________

(1) As of September 30, 2026, the Company has utilized interest rate swaps to fix SOFR and achieve a weighted average fixed interest rate of 3.32% plus the applicable spread on $100 million of the outstanding balance on the Company’s Revolving Credit Facility.
(2) As of September 30, 2026, the Company has utilized interest rate swaps to fix SOFR and achieve a weighted average fixed interest rate of 3.36% plus the applicable spread for the $100 million 2029 Term Loan balance.
(3) As of September 30, 2026, the Company has utilized interest rate swaps to fix SOFR and achieve a weighted average fixed interest rate of 2.05% plus the applicable spread for the $100 million 2031 Term Loan balance.

As of September 30, 2026, the Company held a 93.6% common interest in Alpine Income Property OP, LP, the Company’s operating partnership (the “Operating Partnership” or “OP”). There were 1,223,854 common OP Units held by third parties outstanding and 17,935,407 shares of the Company’s common stock outstanding for a combined total of 19,159,261 shares of common stock and common OP Units held by third parties as of September 30, 2026. 

Dividends

The Company’s dividends for the three and nine months ended September 30, 2026:

           
  Three Months Ended
September 30, 2026
  Nine Months Ended
September 30, 2026
Preferred Dividends Declared and Paid per Share $ 0.500     $ 1.500  
Common Dividends Declared and Paid per Share $ 0.320     $ 0.920  
FFO Attributable to Common Stockholders Payout Ratio   58.2 %     55.8 %
AFFO Attributable to Common Stockholders Payout Ratio   58.2 %     55.4 %

2026 Outlook

The Company is revising its 2026 outlook. The Company’s 2026 guidance is based on current plans and a number of assumptions and is subject to risks and uncertainties, many of which are outside the Company’s control, and are more fully described in this press release and the Company’s reports filed with the U.S. Securities and Exchange Commission. Further, the Company’s 2026 outlook does not reflect the impact of any incentive management fee that may be due to our manager based on stockholder return for the calendar year.

The Company’s revised outlook for 2026 is as follows:

         
(Unaudited)   Prior 2026
Outlook (1)
  Revised 2026
Outlook
Net Income per Diluted Share   $0.81 to $0.84   $0.90 to $0.93
FFO Attributable to Common Stockholders per Diluted Share   $2.10 to $2.13   $2.19 to $2.21
AFFO Attributable to Common Stockholders per Diluted Share   $2.12 to $2.15   $2.20 to $2.22
Investment Volume   $170 to $200 Million   $310 to $350 Million
Disposition Volume   $20 to $40 Million   $20 to $40 Million

____________

(1) As issued on July 23, 2026.

Reconciliation of the outlook range of the Company’s 2026 estimated Net Income per Diluted Share to estimated FFO Attributable to Common Stockholders per Diluted Share, and AFFO Attributable to Common Stockholders per Diluted Share:

             
    Revised Outlook
Range for 2026
(Unaudited)   Low   High
Net Income per Diluted Share   $ 0.90     $ 0.93  
Depreciation and Amortization     1.59       1.58  
Provision for Impairment (1)     0.04       0.04  
Gain on Disposition of Assets (1)     (0.02 )     (0.02 )
FFO per Diluted Share   $ 2.51     $ 2.53  
Distributions to Preferred Stockholders     (0.32 )     (0.32 )
Funds From Operations Attributable to Common Stockholders per Diluted Share   $ 2.19     $ 2.21  
Amortization of Intangible Assets and Liabilities to Lease Income     (0.05 )     (0.06 )
Straight-Line Rent Adjustment     (0.04 )     (0.04 )
Non-Cash Compensation     0.02       0.02  
Amortization of Deferred Financing Costs to Interest Expense     0.06       0.06  
Other Non-Cash Adjustments     0.02       0.03  
AFFO Attributable to Common Stockholders per Diluted Share   $ 2.20     $ 2.22  

____________

(1) Provision for Impairment and Gain on Disposition of Assets represents the actual adjustment for the nine months ended September 30, 2026. The Company’s outlook excludes projections related to these measures.

Third Quarter 2026 Earnings Conference Call & Webcast

The Company will host a conference call to present its operating results for the three and nine months ended September 30, 2026, on Friday, October 23, 2026 at 9:00 AM ET.

A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.alpinereit.com or at the link provided in the event details below. To access the call by phone, please go to the link provided in the event details below and you will be provided with dial-in details.

  Webcast: https://edge.media-server.com/mmc/p/gx2epmx6
  Dial-In:  https://register-conf.media-server.com/register/BIdda2983b5d4a42ac87f47a22c6553594

We encourage participants to dial into the conference call at least fifteen minutes ahead of the scheduled start time. A replay of the earnings call will be archived and available online through the Investor Relations section of the Company’s website at www.alpinereit.com.

About Alpine Income Property Trust, Inc.

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased commercial income properties that are predominately leased to high-quality publicly traded and credit-rated tenants. The Company also complements its income property portfolio by strategically investing in a select portfolio of commercial loan investments intended to deliver an attractive risk-adjusted return.

We encourage you to review our most recent investor presentation which is available on our website at http://www.alpinereit.com.

Safe Harbor

This press release may contain “forward-looking statements.” Forward-looking statements include statements that may be identified by words such as “outlook,” “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include general business and economic conditions, continued volatility and uncertainty in the credit markets and broader financial markets, geopolitical conflicts, tariffs and international trade policies, risks inherent in the real estate business, including tenant or borrower defaults, potential liability relating to environmental matters, credit risk associated with the Company investing in commercial loans and investments, illiquidity of real estate investments and potential damages from natural disasters, the impact of epidemics or pandemics on the Company’s business and the businesses of its tenants and borrowers and the impact of such epidemics or pandemics on the U.S. economy and market conditions generally, other factors affecting the Company’s business or the businesses of its tenants and borrowers that are beyond the control of the Company or its tenants or borrowers, and the factors set forth under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. 

Non-GAAP Financial Measures

Our reported results are presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). We also disclose Funds From Operations (“FFO”), Adjusted Funds From Operations (“AFFO”), and Pro Forma Earnings Before Interest, Taxes, Depreciation and Amortization (“Pro Forma Adjusted EBITDA”), all of which are non-GAAP financial measures. We believe these non-GAAP financial measures are useful to investors because they are widely accepted industry measures used by analysts and investors to compare the operating performance of REITs. 

FFO, AFFO, and Pro Forma Adjusted EBITDA do not represent cash generated from operating activities and are not necessarily indicative of cash available to fund cash requirements; accordingly, they should not be considered alternatives to net income or loss as a performance measure or cash flows from operations as reported on our statement of cash flows as a liquidity measure and should be considered in addition to, and not in lieu of, GAAP financial measures. 

We compute FFO in accordance with the definition adopted by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT. NAREIT defines FFO as GAAP net income or loss adjusted to exclude real estate related depreciation and amortization, as well as extraordinary items (as defined by GAAP) such as net gain or loss from sales of depreciable real estate assets, impairment write-downs associated with depreciable real estate assets and impairments associated with the implementation of current expected credit losses on commercial loans and investments at the time of origination, including the pro rata share of such adjustments of unconsolidated subsidiaries. The Company also excludes the gains or losses from sales of assets incidental to the primary business of the REIT which specifically include the sales of investment securities, if any, in addition to the mark-to-market of the Company’s investment securities.

To derive AFFO, we further modify the NAREIT computation of FFO to include other adjustments to GAAP net income related to non-cash revenues and expenses such as loss on extinguishment of debt, amortization of above- and below-market lease related intangibles, straight-line rental revenue, amortization of deferred financing costs, non-cash compensation, and other non-cash adjustments to income or expense. Such items may cause short-term fluctuations in net income or loss but have no impact on operating cash flows or long-term operating performance. We use AFFO as one measure of our performance when we formulate corporate goals. 

To derive Pro Forma Adjusted EBITDA, GAAP net income or loss is adjusted to exclude extraordinary items (as defined by GAAP), net gain or loss from sales of depreciable real estate assets, impairment write-downs associated with depreciable real estate assets and impairments associated with the implementation of current expected credit losses on commercial loans and investments at the time of origination and/or payoff, and real estate related depreciation and amortization including the pro rata share of such adjustments of unconsolidated subsidiaries, non-cash revenues and expenses such as straight-line rental revenue, amortization of deferred financing costs, loss on extinguishment of debt, above- and below-market lease related intangibles, non-cash compensation, other non-cash income or expense, and other non-recurring items such as disposition management fees and commission fees. The Company also excludes the gains or losses from sales of assets incidental to the primary business of the REIT which specifically include the sales of investment securities, if any, in addition to the mark-to-market of the Company’s investment securities. Cash interest expense is also excluded from Pro Forma Adjusted EBITDA, and GAAP net income or loss is adjusted for the annualized impact of acquisitions, dispositions and other similar activities.

FFO is used by management, investors and analysts to facilitate meaningful comparisons of operating performance between periods and among our peers primarily because it excludes the effect of real estate depreciation and amortization and net gains or losses on sales, which are based on historical costs and implicitly assume that the value of real estate diminishes predictably over time, rather than fluctuating based on existing market conditions. We believe that AFFO is an additional useful supplemental measure for investors to consider because it will help them to better assess our operating performance without the distortions created by other non-cash revenues or expenses. We also believe that Pro Forma Adjusted EBITDA is an additional useful supplemental measure for investors to consider as it allows for a better assessment of our operating performance without the distortions created by other non-cash revenues, expenses or certain effects of the Company’s capital structure on our operating performance. FFO, AFFO, and Pro Forma Adjusted EBITDA may not be comparable to similarly titled measures employed by other companies.

GAAP requires that the Sale-Leaseback and Sales-Type Lease Properties and the value of participation obligation interests sold (the “Participation Obligations Sold”) for which sale accounting was not achieved be accounted for as financing arrangements. Accordingly, for GAAP purposes, the Sale-Leaseback and Sales-Type Lease Properties and Participation Obligations Sold are included in the Company’s Commercial Loans and Investments segment. However, for statistical purposes, the Company excludes the Sale-Leaseback and Sales-Type Lease Properties and the Participation Obligations Sold. Please see page 14 of this press release for further details. We believe that the Supplemental Disclosure on Commercial Loans and Investments is an additional useful measure for investors to consider because it will help them to better assess the performance of our Commercial Loan Portfolio.

Other Definitions

Annualized Base Rent (ABR) represents the annualized in-place straight-line base rent pursuant to GAAP.

Annualized In-Place Cash Base Rent represents the annualized in-place contractual minimum base rent on a cash basis.

Credit Rated Tenant is a tenant or the parent of a tenant with a credit rating from S&P Global Ratings, Moody’s Investors Service, Fitch Ratings or the National Association of Insurance Commissioners.

Investment Grade Rated Tenant is a tenant or the parent of a tenant with a credit rating from S&P Global Ratings, Moody’s Investors Service, Fitch Ratings or the National Association of Insurance Commissioners of Baa3, BBB-, or NAIC-2 or higher. If applicable, in the event of a split rating between S&P Global Ratings and Moody’s Investors Services, the Company utilizes the higher of the two ratings as its reference point as to whether a tenant is defined as an Investment Grade Rated Tenant. Credit ratings utilized in this press release are those available from S&P Global Ratings and/or Moody’s Investors Service, as applicable, as of September 30, 2026.

Weighted Average Remaining Lease Term is weighted by the ABR and does not assume the exercise of any tenant purchase options.

Alpine Income Property Trust, Inc.
Consolidated Balance Sheets
(In thousands, except share and per share data)

           
  As of
  (Unaudited) September 30, 2026   December 31, 2025
ASSETS      
Real Estate:          
Land, at Cost $ 175,167     $ 151,628  
Building and Improvements, at Cost   373,114       344,138  
Total Real Estate, at Cost   548,281       495,766  
Less, Accumulated Depreciation   (66,967 )     (54,446 )
Real Estate—Net   481,314       441,320  
Assets Held for Sale   966       8,077  
Commercial Loans and Investments   231,421       167,553  
Cash and Cash Equivalents   11,722       4,589  
Restricted Cash   19,139       34,410  
Intangible Lease Assets—Net   47,888       48,925  
Straight-Line Rent Adjustment   2,597       2,092  
Other Assets   26,059       8,908  
Total Assets $ 821,106     $ 715,874  
LIABILITIES AND EQUITY          
Liabilities:          
Accounts Payable, Accrued Expenses, and Other Liabilities $ 16,647     $ 7,877  
Prepaid Rent and Deferred Revenue   14,286       14,031  
Intangible Lease Liabilities—Net   6,120       4,971  
Obligation Under Participation Agreement   18,519       10,000  
Long-Term Debt—Net   396,676       377,739  
Total Liabilities   452,248       414,618  
Commitments and Contingencies          
Equity:          
Preferred Stock, 100 million shares authorized, $0.01 par value per share, 8.00% Series A Cumulative Redeemable Preferred Stock, $25.00 Per Share Liquidation Preference, 2,489,747 shares issued and outstanding as of September 30, 2026 and 2,083,328 shares issued and outstanding as of December 31, 2025   25       21  
Common Stock, $0.01 par value per share, 500 million shares authorized, 17,935,407 shares issued and outstanding as of September 30, 2026 and 14,783,419 shares issued and outstanding as of December 31, 2025   179       148  
Additional Paid-in Capital   383,408       313,690  
Dividends in Excess of Net Income   (43,689 )     (35,276 )
Accumulated Other Comprehensive Income   7,452       1,293  
Stockholders’ Equity   347,375       279,876  
Noncontrolling Interest   21,483       21,380  
Total Equity   368,858       301,256  
Total Liabilities and Equity $ 821,106     $ 715,874  


Alpine Income Property Trust, Inc.
Consolidated Statements of Operations
(Unaudited)
(In thousands, except share, per share and dividend data)

                         
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026   2025   2026   2025
Revenues:                        
Lease Income   $ 12,812     $ 12,122     $ 38,051     $ 35,970  
Interest Income from Commercial Loans and Investments     7,611       2,320       20,700       7,358  
Other Revenue     37       121       117       304  
Total Revenues     20,460       14,563       58,868       43,632  
Operating Expenses:                        
Real Estate Expenses     2,095       1,891       6,482       6,030  
General and Administrative Expenses     2,009       1,695       5,896       5,108  
Provision for Impairment and Adjustment to CECL Reserve     (76 )     1,915       809       6,749  
Depreciation and Amortization     6,881       6,597       20,901       20,609  
Total Operating Expenses     10,909       12,098       34,088       38,496  
Gain (Loss) on Disposition of Assets     272       (46 )     369       2,043  
Net Income From Operations     9,823       2,419       25,149       7,179  
Investment and Other Income     17       68       472       160  
Interest Expense     (4,828 )     (3,910 )     (13,760 )     (11,822 )
Net Income (Loss)     5,012       (1,423 )     11,861       (4,483 )
Less: Net Loss (Income) Attributable to Noncontrolling Interest     (324 )     113       (797 )     353  
Net Income (Loss) Attributable to Alpine Income Property Trust, Inc.     4,688       (1,310 )     11,064       (4,130 )
Less: Distributions to Preferred Stockholders     (1,245 )     —       (3,554 )     —  
Net Income (Loss) Attributable to Common Stockholders   $ 3,443     $ (1,310 )   $ 7,510     $ (4,130 )
                         
Per Common Share Data:                        
Net Income (Loss) Attributable to Common Stockholders                        
Basic   $ 0.19     $ (0.09 )   $ 0.45     $ (0.29 )
Diluted   $ 0.18     $ (0.09 )   $ 0.42     $ (0.29 )
                         
Weighted Average Number of Common Shares:                        
Basic     17,694,160       14,158,190       16,776,481       14,328,245  
Diluted (1)     18,918,014       15,382,044       18,000,335       15,552,099  
                         
Dividends Declared and Paid – Preferred Stock   $ 0.500     $ —     $ 1.500     $ —  
Dividends Declared and Paid – Common Stock   $ 0.320     $ 0.285     $ 0.920     $ 0.855  

____________

(1)  Includes 1,223,854 shares during the three and nine months ended September 30, 2026 and 2025, underlying 1,223,854 OP Units issued to CTO Realty Growth, Inc. and its wholly owned subsidiaries.

        

Alpine Income Property Trust, Inc.
Non-GAAP Financial Measures
Funds From Operations and Adjusted Funds From Operations
(Unaudited)
(In thousands, except per share data)

                         
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026   2025   2026   2025
Net Income (Loss)   $ 5,012     $ (1,423 )   $ 11,861     $ (4,483 )
Depreciation and Amortization     6,881       6,597       20,901       20,609  
Provision for Impairment and Adjustment to CECL Reserve     (76 )     1,915       809       6,749  
Loss (Gain) on Disposition of Assets     (272 )     46       (369 )     (2,043 )
Unrealized Loss on Investment Securities     56       —       56       —  
Funds From Operations   $ 11,601     $ 7,135     $ 33,258     $ 20,832  
Distributions to Preferred Stockholders     (1,245 )     —       (3,554 )     —  
Funds From Operations Attributable to Common Stockholders   $ 10,356     $ 7,135     $ 29,704     $ 20,832  
Adjustments:                        
Amortization of Intangible Assets and Liabilities to Lease Income     (256 )     (176 )     (733 )     (422 )
Straight-Line Rent Adjustment     (191 )     (177 )     (508 )     (539 )
Non-Cash Compensation     95       95       285       285  
Amortization of Deferred Financing Costs to Interest Expense     303       197       871       591  
Other Non-Cash Adjustments     116       54       267       162  
Adjusted Funds From Operations Attributable to Common Stockholders   $ 10,423     $ 7,128     $ 29,886     $ 20,909  
                         
FFO Attributable to Common Stockholders per Diluted Share   $ 0.55     $ 0.46     $ 1.65     $ 1.34  
AFFO Attributable to Common Stockholders per Diluted Share   $ 0.55     $ 0.46     $ 1.66     $ 1.34  
                         
Supplemental Disclosure:                        
PIK Interest Earned   $ 900     $ —     $ 2,373     $ —  
PIK Interest Paid     —       —       50       —  
PIK Interest Earned in Excess of PIK Interest Paid   $ 900     $ —     $ 2,323     $ —  


Alpine Income Property Trust, Inc.
Non-GAAP Financial Measures
Reconciliation of Net Debt to Pro Forma Adjusted EBITDA
(Unaudited)
(In thousands)

       
    Three Months Ended September 30, 2026
Net Income   $ 5,012  
Adjustments:      
Depreciation and Amortization     6,881  
Provision for Impairment and Adjustment to CECL Reserve     (76 )
Gain on Disposition of Assets     (272 )
Unrealized Loss on Investment Securities     56  
Distributions to Preferred Stockholders     (1,245 )
Amortization of Intangible Assets and Liabilities to Lease Income     (256 )
Straight-Line Rent Adjustment     (191 )
Non-Cash Compensation     95  
Amortization of Deferred Financing Costs to Interest Expense     303  
Other Non-Cash Adjustments     116  
Other Non-Recurring Items     (22 )
Interest Expense, Net of Deferred Financing Costs Amortization and Interest on Obligation Under Participation Agreement     4,044  
Adjusted EBITDA   $ 14,445  
       
Annualized Adjusted EBITDA   $ 57,780  
Pro Forma Annualized Impact of Current Quarter Investment Activity (1)     1,598  
Pro Forma Adjusted EBITDA   $ 59,378  
       
Total Long-Term Debt   $ 396,676  
Financing Costs, Net of Accumulated Amortization     1,824  
Cash and Cash Equivalents     (11,722 )
Net Debt   $ 386,778  
Net Debt to Pro Forma Adjusted EBITDA     6.5x

____________

(1) Reflects the pro forma annualized impact on Annualized Adjusted EBITDA of the Company’s investment and disposition activity during the three months ended September 30, 2026.

Alpine Income Property Trust, Inc.
Non-GAAP Financial Measures
Supplemental Disclosure on Commercial Loans and Investments
(Unaudited)
(In thousands)

                                 
    As of and for the Nine Months Ended September 30, 2026
    Commercial Loan Portfolio   Plus: Participation Obligations Sold   Total Commercial Loans   Plus: Sale-Leaseback and Sale-Type Lease Transactions   Commercial Loans and Investments Pursuant to GAAP  
Face Amount, Beginning of Period   $ 129,813     $ 10,000     $ 139,813     $ 31,133     $ 170,946    
Draws (Including Accrued PIK Interest)     63,828       10,763       74,591       26,257       100,848    
Principal Repayments     (33,536 )     (2,244 )     (35,780 )     (234 )     (36,014 )  
Face Amount, End of Period     160,105       18,519       178,624       57,156       235,780    
Unaccreted Origination Fees     (2,001 )     —       (2,001 )     —       (2,001 )  
CECL Reserve     (1,601 )     (185 )     (1,786 )     (572 )     (2,358 )  
Carrying Amount, End of Period   $ 156,503     $ 18,334     $ 174,837     $ 56,584     $ 231,421    
                                 
Cash Interest Income   $ 12,747     $ 1,301     $ 14,048     $ 3,226     $ 17,274    
PIK Interest Earned     2,373       —       2,373       —       2,373    
Accretion of Commercial Loans and Investments Origination Fees     1,053       —       1,053       —       1,053    
Total Interest Income   $ 16,173     $ 1,301     $ 17,474     $ 3,226     $ 20,700    
                                 
Weighted Average Coupon Rate, End of Period (1)     13.4   %   10.0   %   13.0   %   8.3   %   11.9   %

____________

(1) Includes PIK interest coupon rate.

CONTACT: Contact:        
Investor Relations
ir@alpinereit.com

Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume

Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug application for ARD-101 for the treatment of hyperphagia in PWS.

“We are pleased that the FDA has lifted the clinical hold on ARD-101, allowing us to continue advancing our clinical development program,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “With strong alignment and collaboration with the FDA, we completed the work necessary to allow for the resumption of clinical studies. People living with PWS and their families continue to face profound unmet need, and we look forward to working with the FDA as we advance ARD-101.”

On February 27, 2026, Aardvark voluntarily paused dosing in the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and its open-label extension (OLE) trial following reversible electrocardiogram (ECG) changes observed during routine safety monitoring in a separate study in healthy volunteers. In May 2026, the FDA placed a clinical hold on the HERO trial and OLE trial. In alignment with the FDA, the Company conducted a thorough ECG study in additional healthy volunteers and an in vitro cardiac sodium channel (NaV1.5) study. No cardiac events were observed in the recently completed ECG study at ARD-101 doses of 200 mg and 400 mg twice daily.

Aardvark plans to resume clinical development of ARD-101 in patients with PWS following additional anticipated engagement and alignment with the FDA on the Phase 3 trial design. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data.

Conference Call and Webcast

The Company will host a live conference call and webcast for investors to discuss data from the terminated HERO and OLE trials tomorrow, October 23, 2026, at 8:00 AM ET. To access the live conference call, participants may register here. To access the live webcast and subsequent archived recording of this event, please visit the Investors section of Aardvark’s website.

About ARD-101

ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 is being developed as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.

About Aardvark Therapeutics, Inc.

Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, the path forward for ARD-101, including the anticipated resumption of the clinical development of ARD-101 and any further engagement and alignment with the FDA prior to such resumption, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the risk that the FDA may not agree with Aardvark’s proposed Phase 3 program or may require additional studies; limitations in interpreting data from the HERO trial and its OLE trial, which were terminated early and were not powered to assess efficacy; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; the risk that Aardvark may use its capital resources sooner than expected; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

Investor and Media Contact
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com 

RALEIGH, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) announces its Board of Directors has declared a cash dividend of $0.50 per share of common stock for the quarter ended September 30, 2026, which equates to an annualized dividend of $2.00 per share. This quarterly dividend is payable on December 8, 2026 to all holders of record as of November 16, 2026.

The Board also declared a cash dividend of $21.5625 per share of the Company’s 8 5/8% Series A Cumulative Redeemable Preferred Stock. The dividend is payable on November 30, 2026 which is the next regularly scheduled dividend payment date, to all holders of record as of November 16, 2026.

About Highwoods
Highwoods Properties, Inc., headquartered in Raleigh, is a publicly-traded (NYSE:HIW), fully-integrated office real estate investment trust (“REIT”) that owns, develops, acquires, leases and manages properties primarily in the best business districts (BBDs) of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh and Tampa. Our vision is to be a leader in the evolution of commercial real estate for the benefit of our customers, our communities and those who invest with us. Our mission is to create environments and experiences that inspire our teammates and our customers to achieve more together. We are in the work-placemaking business and believe that by creating exceptional environments and experiences, we can deliver greater value to our customers, their teammates and, in turn, our shareholders. For more information about Highwoods, please visit our website at www.highwoods.com.

Contact: Brendan Maiorana
  Executive Vice President and Chief Financial Officer
  brendan.maiorana@highwoods.com
  919-872-4924

ALEXANDRIA, Va., Oct. 22, 2026 (GLOBE NEWSWIRE) — Burke & Herbert Financial Services Corp. (the “Company” or “Burke & Herbert”) (Nasdaq: BHRB) reported financial results for the quarter ended September 30, 2026. In addition, at its meeting on October 22, 2026, the board of directors declared a $0.55 per share regular cash dividend to be paid on December 1, 2026, to shareholders of record as of the close of business on November 13, 2026.

From David P. Boyle, Company Chair and Chief Executive Officer

“Our third quarter results reflect disciplined execution and continued momentum across the Company. Core earnings were strong, asset quality remains consistent with our moderate risk profile, and we once again delivered top-quartile returns compared to our peers. We also completed a $100 million subordinated debt offering, further strengthening our capital position and providing additional financial flexibility to support profitable growth. Our team continues to execute well, and we remain focused on delivering long-term value for our shareholders, customers, employees, and communities.”

Q3 2026 Highlights

  • Financial results reflect a full quarter following the May 1, 2026, completion of the merger of LINKBANCORP, Inc. (“LNKB”), with and into Burke & Herbert and the merger of LINKBANK with and into Burke & Herbert Bank & Trust Company.
  • The Company reported net income applicable to common shares of $36.2 million for the quarter and diluted earnings per common share (“EPS”) of $1.78; excluding merger-related items and other related items, adjusted (non-GAAP1) operating net income applicable to common shares was $43.4 million for the quarter and adjusted (non-GAAP1) diluted EPS was $2.14.
  • For the quarter, the annualized return on average assets (“ROA”) was 1.30%, the annualized return on average common equity (“ROCE”) was 12.02%, and the annualized return on average tangible common equity (“ROATCE”) (non-GAAP1) was 14.14%.
  • On an adjusted basis (non-GAAP1), ROA was 1.57%, ROCE was 14.42%, and ROATCE was 16.96%.
  • Total shareholders’ equity was $1.2 billion and tangible common equity to tangible assets (non-GAAP1) was 8.77%, reflecting the Company’s strong capital position.
  • Ending total gross loans were $8.1 billion and ending total deposits were $9.0 billion; ending loan-to-deposit ratio was 90.0%. The net interest margin (non-GAAP1) was 4.21% for the three months ended September 30, 2026.
  • The balance sheet remains strong with ample liquidity. Total liquidity, including all available borrowing capacity with cash and cash equivalents, totaled $6.5 billion at the end of the third quarter.
  • The Company continues to be well-capitalized, ending the quarter with 12.03%2 Common Equity Tier 1 capital to risk-weighted assets, 15.45%2 Total risk-based capital to risk-weighted assets, and a leverage ratio of 10.43%.2

Results of Operations

Third Quarter 2026 compared to Second Quarter 2026

The Company reported third quarter 2026 net income applicable to common shares of $36.2 million, or $1.78 per diluted common share, compared to second quarter 2026 net income applicable to common shares of $9.3 million, or $0.50 per diluted common share.

  • Period-end total gross loans were $8.1 billion at September 30, 2026, an increase of $62.2 million from June 30, 2026. The Company originated $406.9 million of new, relationship-based loan commitments during the quarter.
  • Period-end total deposits were $9.0 billion at September 30, 2026, a decrease of $12.4 million from June 30, 2026. Brokered deposits totaled $120.7 million at September 30, 2026, which represented only 1.35% of total deposits.
  • Net interest income for the quarter was $105.0 million compared to $93.0 million in the prior quarter due to an increase in interest income of $17.7 million, which was partially offset by an increase in interest expense of $5.8 million, primarily due to the full quarter impact of LNKB.
  • Net interest margin on a fully taxable-equivalent basis (non-GAAP1) increased to 4.21% versus 4.15% in the second quarter of 2026, driven by growth in both the average balance on total loans and higher yields on total loans, partially offset by higher funding costs. The increase reflected a full quarter of LNKB results and a rising interest rate environment.
  • Accretion income on loans during the quarter was $9.3 million, and the amortization expense impact on interest expense was $1.5 million, or 30.4 bps of net interest margin on an annualized basis in the third quarter of 2026. In the prior quarter, accretion income on loans during the quarter was $9.3 million, and the amortization expense impact on interest expense was $1.5 million, or 34.0 bps of net interest margin on an annualized basis.
  • The cost of total deposits, including non-interest bearing deposits, was 1.83% in the third quarter of 2026, compared to 1.75% in the second quarter of 2026. The increase in the cost of deposits was mostly due to increases in both the average balance of total interest-bearing deposits and the rates paid on total interest-bearing deposits compared to the second quarter of 2026. The increase reflected a full quarter of LNKB results and a rising interest rate environment.
  • The Company recorded credit provision expense in the third quarter of 2026 of $1.5 million on loans and a recapture of credit loss expense of $0.8 million on unfunded commitments. The Company’s allowance for credit losses as of September 30, 2026, was $92.5 million, or 1.15% of total loans. Asset quality metrics remain within the Company’s moderate risk profile with adequate reserve coverage. Total delinquencies increased $4.9 million to $89.6 million during the quarter, and nonperforming loans increased $12.7 million to $108.0 million during the quarter; however, the increases were concentrated in a limited number of isolated credits and do not reflect broad-based deterioration in the loan portfolio. We do not currently expect these credits to result in material charge-offs, and nonperforming loans remain at 1.34% of total loans, below 1.60% a year ago.
  • Total non-interest income increased $873.0 thousand to $14.7 million in the third quarter of 2026, compared to $13.8 million in the second quarter of 2026. The second quarter included transactions related to LNKB resulting in a loss of $1.9 million offset by company-owned life insurance income. Despite the absence of these items, non-interest income increased due to an additional month of combined debit card income and higher fiduciary and wealth management income.
  • Non-interest expense for the third quarter of 2026 was $74.5 million compared to $93.5 million in the second quarter of 2026; adjusted non-interest expense for the third quarter of 2026 was $65.3 million compared to $61.1 million in the second quarter of 2026, the increase primarily due to the full quarter impact of LNKB.

Regulatory capital ratios2

The Company continues to be well-capitalized with capital ratios that are above regulatory requirements. As of September 30, 2026, our Common Equity Tier 1 capital to risk-weighted asset and Total risk-based capital to risk-weighted asset ratios were 12.03%2 and 15.45%2, respectively, and significantly above the well-capitalized requirements of 6.5% and 10%, respectively. The leverage ratio was 10.43%2 compared to a 5% level to be considered well-capitalized.

Burke & Herbert Bank & Trust Company (the “Bank”), the Company’s wholly-owned bank subsidiary, also continues to be well-capitalized with capital ratios that are above regulatory requirements. As of September 30, 2026, the Bank’s Common Equity Tier 1 capital to risk-weighted asset and Total risk-based capital to risk-weighted asset ratios were 13.36%2 and 14.35%,2 respectively, and significantly above the well-capitalized requirements. In addition, the Bank’s leverage ratio of 11.20%2 is considered to be well-capitalized.

For more information about the Company’s financial condition, including additional disclosures pertinent to recent events in the banking industry, please see our financial statements and supplemental information attached to this release.

About Burke & Herbert

Burke & Herbert Financial Services Corp. is the financial holding company for Burke & Herbert Bank & Trust Company. Burke & Herbert Bank & Trust Company is the oldest continuously operating bank under its original name headquartered in the greater Washington, D.C. metropolitan area. With over 100 branches across Delaware, Kentucky, Maryland, Pennsylvania, Virginia, and West Virginia, Burke & Herbert Bank & Trust Company offers a full range of business and personal financial solutions designed to meet customers’ banking, borrowing, and investment needs. Learn more at investor.burkeandherbertbank.com.

Cautionary Note Regarding Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to (or based on) the beliefs, goals, intentions, and expectations of Burke & Herbert regarding our: merger with LINKBANCORP, Inc., effective as of May 1, 2026, and the expected cost savings, synergies, returns, and other anticipated benefits from the integration of LNKB; revenues, earnings, earnings per share, loan production, asset quality, and capital levels, among other matters; estimates of the future costs and benefits of the actions we may take; assessments of expected losses on loans; assessments of interest rate and other market risks; ability to achieve financial and other strategic goals; and other statements that are not historical facts. Forward–looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “will,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks, and uncertainties, which change over time.

Additionally, forward–looking statements speak only as of the date they are made; Burke & Herbert does not assume any duty, and does not undertake, to update such forward–looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise. Furthermore, because forward–looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those indicated in or implied by such forward-looking statements as a result of a variety of factors, many of which are beyond the control of Burke & Herbert. Such statements are based upon the current beliefs and expectations of the management of Burke & Herbert and are subject to significant risks and uncertainties outside of its control. Caution should be exercised against placing undue reliance on forward-looking statements.

The factors that could cause actual results to differ materially include the following: the possibility that the anticipated benefits of the merger will not be realized when expected or at all, including as a result of the impact of, or problems arising from (if any), the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Burke & Herbert and LNKB do business; costs or difficulties associated with newly developed or acquired operations; diversion of management’s attention from ongoing business operations and opportunities; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected timeframes or at all and to successfully integrate LNKB’s operations and those of Burke & Herbert; that the integration of LNKB may be more difficult, time-consuming or costly than expected; revenues following the merger may be lower than expected; Burke & Herbert’s success in executing its business plans and strategies and managing the risks involved in the foregoing; and risks related to the potential impact of global macroeconomic conditions and changes in general economic, political, and market factors on the merger or our operations, generally (either nationally or locally in the areas in which we conduct, or will conduct, business), including inflation, changes in interest rates, market volatility and monetary fluctuations, and changes in federal government policies and practices, including the impact with respect to spending on industries concentrated in our market area, as well as the impact from tariffs on the markets we serve; increased competition; changes in consumer confidence and demand for financial services, including changes in consumer borrowing, repayment, investment, and deposit practices; changes in asset quality and credit risk; our ability to control costs and expenses; adverse developments in borrower industries or declines in real estate values; changes in and compliance with federal and state laws and regulations that pertain to our business and capital levels; our ability to raise capital as needed; the impact, extent and timing of technological changes; emerging external focus among regulators and other officials related to risks in connection with the development and use of artificial intelligence; the effects of any cybersecurity breaches or events; the potential adverse effects of unusual and infrequently occurring events, such as weather-related disasters, terrorist acts, geopolitical conflicts and tensions, or public health events (such as pandemics), and of governmental and societal responses thereto; and the other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Burke & Herbert’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, and June 30, 2026, and other reports Burke & Herbert files with the SEC.

Burke & Herbert Financial Services Corp.
Consolidated Statements of Income (unaudited)
(In thousands)

    Three Months Ended   Nine Months Ended
    September 30,   June 30,   September 30,
    2026   2025   2026   2026   2025
Interest income                    
Taxable loans, including fees   $ 134,060     $ 95,132     $ 116,770     $ 338,913   $ 288,966  
Tax-exempt loans, including fees     63       47       55       158     136  
Taxable securities     10,271       9,062       11,329       31,358     27,852  
Tax-exempt securities     8,316       4,863       7,605       22,003     12,069  
Other interest income     2,014       2,105       1,228       4,735     4,830  
Total interest income     154,724       111,209       136,987       397,167     333,853  
Interest expense                    
Deposits     41,275       30,286       35,018       103,013     92,568  
Short-term borrowings     4,717       4,379       5,897       15,204     12,009  
Subordinated debt     3,677       2,748       2,990       8,936     8,207  
Other interest expense     39       26       40       113     79  
Total interest expense     49,708       37,439       43,945       127,266     112,863  
Net interest income     105,016       73,770       93,042       269,901     220,990  
                     
Credit loss expense (recapture) – loans and available-for-sale securities     1,493       574       (833 )     873     2,191  
Credit loss expense (recapture) – off-balance sheet credit exposures     (790 )     (312 )     2,212       1,221     (804 )
Total provision for credit losses     703       262       1,379       2,094     1,387  
Net interest income after credit loss expense     104,313       73,508       91,663       267,807     219,603  
                     
Non-interest income                    
Fiduciary and wealth management     3,347       2,664       3,100       9,674     7,532  
Service charges and fees     2,570       2,070       2,286       6,711     6,195  
Net gain (loss) on securities     89       212       (1,868 )     20     251  
Income from company-owned life insurance     2,078       1,152       3,207       6,764     5,327  
Bank debit and other card revenue     3,625       3,192       3,421       9,881     9,100  
Other non-interest income     3,013       2,295       3,703       8,374     6,080  
Total non-interest income     14,722       11,585       13,849       41,424     34,485  
                     
Non-interest expense                    
Salaries and wages     32,816       20,848       41,378       95,607     63,109  
Pensions and other employee benefits     6,229       4,429       5,787       17,386     13,632  
Occupancy     4,941       3,479       6,654       15,622     11,045  
Equipment rentals, depreciation and maintenance     5,385       3,908       6,934       16,507     12,092  
Core deposit intangible amortization     6,352       3,683       5,530       15,566     11,869  
ATM, card and network expense     1,799       1,200       1,389       4,322     3,646  
FDIC and other regulatory assessments     1,198       976       1,576       3,914     2,978  
Other operating     15,757       9,569       24,258       50,440     28,690  
Total non-interest expense     74,477       48,092       93,506       219,364     147,061  
Income before income taxes     44,558       37,001       12,006       89,867     107,027  
                     
Income tax expense     8,171       7,037       2,524       16,649     19,965  
Net income     36,387       29,964       9,482       73,218     87,062  
Preferred stock dividends     225       225       225       675     675  
Net income applicable to common shares   $ 36,162     $ 29,739     $ 9,257     $ 72,543   $ 86,387  
                     
Earnings per common share                    
Basic   $ 1.79     $ 1.98     $ 0.50     $ 4.05   $ 5.76  
Diluted     1.78       1.97       0.50       4.03     5.74  
                     

Burke & Herbert Financial Services Corp.
Consolidated Balance Sheets
(In thousands)

    September 30, 2026   December 31, 2025
    (Unaudited)   (Audited)
Assets        
Cash and due from banks   $ 101,308     $ 53,497  
Interest-earning deposits with banks     43,088       235,630  
Cash and cash equivalents     144,396       289,127  
Securities available-for-sale, at fair value     1,943,142       1,615,954  
Restricted stock, at cost     58,999       42,187  
Loans held-for-sale, at fair value     2,202       365  
Loans     8,061,967       5,387,676  
Allowance for credit losses     (92,473 )     (67,823 )
Net loans     7,969,494       5,319,853  
Other real estate owned     2,873       2,689  
Premises and equipment, net     148,370       136,809  
Accrued interest receivable     48,725       35,442  
Intangible assets     74,402       41,747  
Goodwill     118,345       34,149  
Company-owned life insurance     270,917       213,200  
Other assets     252,528       189,104  
Total Assets   $ 11,034,393     $ 7,920,626  
         
Liabilities and Shareholders’ Equity        
Liabilities        
Non-interest-bearing deposits   $ 2,015,942     $ 1,336,380  
Interest-bearing deposits     6,939,693       5,067,561  
Total deposits     8,955,635       6,403,941  
Short-term borrowings     525,000       450,000  
Subordinated debentures, net     233,935       70,222  
Subordinated debentures owed to unconsolidated subsidiary trusts     17,458       17,268  
Accrued interest and other liabilities     148,621       124,546  
Total Liabilities     9,880,649       7,065,977  
         
Shareholders’ Equity        
Preferred stock and surplus     10,413       10,413  
Common stock     10,382       7,800  
Common stock, additional paid-in capital     736,232       405,922  
Retained earnings     558,786       517,058  
Accumulated other comprehensive income (loss)     (134,485 )     (58,960 )
Treasury stock     (27,584 )     (27,584 )
Total Shareholders’ Equity     1,153,744       854,649  
Total Liabilities and Shareholders’ Equity   $ 11,034,393     $ 7,920,626  


Burke & Herbert Financial Services Corp.
Details of Net Interest Margin (unaudited)
For the three months ended

Details of Net Interest Margin – Yield Percentages
                   
  September 30   June 30   March 31   December 31   September 30
  2026   2026   2026   2025   2025
Interest-earning assets:
Loans:                  
Taxable loans 6.69 %   6.54 %   6.64 %   6.79 %   6.76 %
Tax-exempt loans 6.29     6.15     7.12     7.03     6.78  
Total loans 6.69     6.54     6.64     6.79     6.76  
Interest-earning deposits and fed funds sold 3.55     3.28     4.25     3.83     4.33  
Securities:                  
Taxable securities 3.97     4.23     3.78     3.78     3.86  
Tax-exempt securities 4.66     4.65     4.48     4.27     4.17  
Total securities 4.27     4.41     4.05     3.96     3.97  
Total interest-earning assets 6.17 %   6.06 %   5.97 %   6.06 %   6.11 %
                   
Interest-bearing liabilities:
Deposits:                  
Interest-bearing demand 2.07 %   1.96 %   1.98 %   2.07 %   2.18 %
Money market & savings 1.99     1.95     1.83     1.94     2.02  
Brokered CDs & time deposits 3.34     3.27     3.11     3.23     3.25  
Total interest-bearing deposits 2.36     2.25     2.16     2.28     2.37  
Borrowings:                  
Short-term borrowings 3.55     3.64     3.78     3.93     3.85  
Subordinated debt borrowings and other 9.49     9.16     10.46     10.62     9.49  
Total interest-bearing liabilities 2.59 %   2.51 %   2.44 %   2.54 %   2.63 %
                   
Taxable-equivalent net interest spread 3.58     3.55     3.53     3.52     3.48  
Benefit from use of non-interest-bearing deposits 0.63     0.60     0.56     0.59     0.60  
Taxable-equivalent net interest margin (non-GAAP1) 4.21 %   4.15 %   4.09 %   4.11 %   4.08 %


Burke & Herbert Financial Services Corp.
Details of Net Interest Margin (unaudited)
For the three months ended
(In thousands)

Details of Net Interest Margin – Average Balances
                   
  September 30   June 30   March 31   December 31   September 30
  2026   2026   2026   2025   2025
                   
Interest-earning assets:
Loans:                  
Taxable loans $ 7,951,809   $ 7,156,639   $ 5,380,967   $ 5,482,574   $ 5,584,315
Tax-exempt loans   5,047     4,497     2,903     3,159     3,511
Total loans   7,956,856     7,161,136     5,383,870     5,485,733     5,587,826
Interest-earning deposits and fed funds sold   118,138     69,525     70,361     222,990     100,445
Securities:                  
Taxable securities   1,123,098     1,137,512     1,128,486     1,031,603     1,034,136
Tax-exempt securities   896,752     830,459     696,580     623,417     586,129
Total securities   2,019,850     1,967,971     1,825,066     1,655,020     1,620,265
Total interest-earning assets $ 10,094,844   $ 9,198,632   $ 7,279,297   $ 7,363,743   $ 7,308,536
                   
Interest-bearing liabilities:
Deposits:                  
Interest-bearing demand $ 3,002,772   $ 2,706,931   $ 2,286,206   $ 2,315,064   $ 2,278,587
Money market & savings   2,223,150     2,106,402     1,675,034     1,705,028     1,660,401
Brokered CDs & time deposits   1,715,509     1,421,123     1,044,605     1,100,215     1,135,546
Total interest-bearing deposits   6,941,431     6,234,456     5,005,845     5,120,307     5,074,534
Borrowings:                  
Short-term borrowings   531,335     653,886     496,501     453,436     453,486
Subordinated debt borrowings and other   153,724     130,913     87,979     86,635     114,900
Total interest-bearing liabilities $ 7,626,490   $ 7,019,255   $ 5,590,325   $ 5,660,378   $ 5,642,920
                   
Non-interest-bearing deposits $ 2,029,261   $ 1,802,833   $ 1,332,090   $ 1,358,798   $ 1,338,188

  

Burke & Herbert Financial Services Corp.
Supplemental Information (unaudited)
As of or for the three months ended
(In thousands, except ratios and per share amounts)

  September 30   June 30   March 31   December 31   September 30
  2026   2026   2026   2025   2025
                   
Per common share information
Basic earnings $ 1.79     $ 0.50     $ 1.80     $ 2.00     $ 1.98  
Diluted earnings   1.78       0.50       1.79       1.98       1.97  
Cash dividends   0.55       0.55       0.55       0.55       0.55  
Book value per common share   56.62       59.10       56.77       56.18       54.02  
Tangible book value per common share (non-GAAP1)   47.07       49.23       51.83       51.13       48.72  
                   
Balance sheet-related (at period end, unless otherwise indicated)
Assets $ 11,034,393     $ 10,991,300     $ 7,927,711     $ 7,920,626     $ 7,889,037  
Average interest-earning assets   10,094,844       9,198,632       7,279,297       7,363,743       7,308,536  
Loans (gross)   8,061,967       7,999,765       5,404,667       5,387,676       5,559,479  
Loans (net)   7,969,494       7,905,295       5,336,712       5,319,853       5,491,875  
Securities, available-for-sale, at fair value   1,943,142       1,963,038       1,826,037       1,615,954       1,598,407  
Intangible assets   74,402       80,754       38,063       41,747       45,431  
Goodwill   118,345       118,345       36,253       34,149       34,149  
Non-interest-bearing deposits   2,015,942       2,058,076       1,367,050       1,336,380       1,358,250  
Interest-bearing deposits   6,939,693       6,910,006       4,965,215       5,067,561       5,053,802  
Deposits, total   8,955,635       8,968,082       6,332,265       6,403,941       6,412,052  
Brokered deposits   120,717       120,667       3,431       64,410       124,386  
Uninsured deposits   3,265,486       3,157,531       2,060,145       2,057,873       2,022,739  
Short-term borrowings   525,000       525,000       525,000       450,000       450,000  
Subordinated debt, net   233,935       152,183       88,841       87,490       86,110  
Unused borrowing capacity3   6,366,769       6,087,369       4,181,408       3,989,887       3,914,854  
Total equity   1,153,744       1,202,179       864,504       854,649       822,231  
Total common equity   1,143,331       1,191,766       854,091       844,236       811,818  
Accumulated other comprehensive income (loss)   (134,485 )     (59,637 )     (69,002 )     (58,960 )     (68,454 )
                   
Asset Quality                  
Provision for credit losses $ 703     $ 1,379     $ 12     $ 136     $ 262  
Net loan charge-offs (recoveries)   2,865       1,159       81       (84 )     226  
Allowance for credit losses   92,473       94,470       67,955       67,823       67,604  
Total delinquencies4   89,550       84,640       93,088       37,080       34,722  
Nonperforming loans5   107,980       95,308       78,559       74,236       89,051  


Burke & Herbert Financial Services Corp.
Supplemental Information (unaudited)
As of or for the three months ended
(In thousands, except ratios and per share amounts)

  September 30   June 30   March 31   December 31   September 30
  2026   2026   2026   2025   2025
Income statement
Interest income $ 154,724     $ 136,987     $ 105,456     $ 111,140     $ 111,209  
Interest expense   49,708       43,945       33,613       36,218       37,439  
Non-interest income   14,722       13,849       12,853       11,625       11,585  
Total revenue (non-GAAP1)   119,738       106,891       84,696       86,547       85,355  
Non-interest expense   74,477       93,506       51,381       48,500       48,092  
Pretax, pre-provision earnings (non-GAAP1)   45,261       13,385       33,315       38,047       37,263  
Provision for credit losses   703       1,379       12       136       262  
Income before income taxes   44,558       12,006       33,303       37,911       37,001  
Income tax expense   8,171       2,524       5,954       7,667       7,037  
Net income   36,387       9,482       27,349       30,244       29,964  
Preferred stock dividends   225       225       225       225       225  
Net income applicable to common shares $ 36,162     $ 9,257     $ 27,124     $ 30,019     $ 29,739  
                   
Ratios
Annualized return on average assets   1.30 %     0.37 %     1.39 %     1.49 %     1.50 %
Annualized return on average common equity   12.02       3.52       12.77       14.31       15.08  
Net interest margin (non-GAAP1)   4.21       4.15       4.09       4.11       4.08  
Efficiency ratio   62.20       87.48       60.67       56.03       56.34  
Loan-to-deposit ratio   90.02       89.20       85.35       84.13       86.70  
Consolidated Common Equity Tier 1 (CET1) capital ratio2   12.03       11.76       13.78       13.45       12.79  
Consolidated Total risk-based capital ratio2   15.45       14.42       16.52       16.17       15.44  
Consolidated Leverage ratio2   10.43       11.07       11.26       10.92       10.71  
Allowance coverage ratio   1.15       1.18       1.26       1.26       1.22  
Allowance for credit losses as a percentage of non-performing loans   85.64       99.12       86.50       91.36       75.92  
Non-performing loans as a percentage of total loans   1.34       1.19       1.45       1.38       1.60  
Non-performing assets as a percentage of total assets   1.00       0.89       1.03       0.97       1.16  
Net charge-offs (recoveries) to average loans (annualized) 14.3 bps   6.5 bps   0.6 bps   (0.6) bps   1.6 bps
                   


Burke & Herbert Financial Services Corp.
Non-GAAP Reconciliations (unaudited)
(In thousands, except ratios and per share amounts)

Operating net income, adjusted diluted EPS, and adjusted non-interest expense (non-GAAP1)
    For the three months ended
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Net income applicable to common shares   $ 36,162   $ 9,257   $ 27,124   $ 30,019   $ 29,739
Add back significant items (tax effected):                    
Merger-related     7,220     28,221     1,114     —     —
Total significant items     7,220     28,221     1,114     —     —
Operating net income   $ 43,382   $ 37,478   $ 28,238   $ 30,019   $ 29,739
                     
Weighted average dilutive shares     20,294,758     18,499,030     15,131,481     15,139,792     15,112,413
Adjusted diluted EPS   $ 2.14   $ 2.03   $ 1.87   $ 1.98   $ 1.97
                     
Non-interest expense   $ 74,477   $ 93,506   $ 51,381   $ 48,500   $ 48,092
Remove significant items:                    
Merger-related     9,139     32,387     1,410     —     —
Total significant items     9,139     32,387     1,410     —     —
Adjusted non-interest expense   $ 65,338   $ 61,119   $ 49,971   $ 48,500   $ 48,092

Operating net income is a non-GAAP measure that is derived from net income adjusted for significant items. The Company believes that operating net income is useful in periods with certain significant items such as merger-related expenses. The operating net income is more reflective of management’s ability to grow the business and manage expenses. Adjusted non-interest expense also removes these significant items, such as merger-related expenses. Management believes it represents a more normalized non-interest expense total for periods with identified significant items.

Total Revenue (non-GAAP1)
    For the three months ended
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Interest income   $ 154,724   $ 136,987   $ 105,456   $ 111,140   $ 111,209
Interest expense     49,708     43,945     33,613     36,218     37,439
Non-interest income     14,722     13,849     12,853     11,625     11,585
Total revenue (non-GAAP1)   $ 119,738   $ 106,891   $ 84,696   $ 86,547   $ 85,355

Total revenue is a non-GAAP measure and is derived from total interest income less total interest expense plus total non-interest income. We believe that total revenue is a useful tool to determine how the Company is managing its business and demonstrates how stable our revenue sources are from period to period.


Burke & Herbert Financial Services Corp.
Non-GAAP Reconciliations (unaudited)
(In thousands, except ratios and per share amounts)

Pretax, Pre-Provision Earnings (non-GAAP1)
    For the three months ended
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Income before income taxes   $ 44,558   $ 12,006   $ 33,303   $ 37,911   $ 37,001
Provision for credit losses     703     1,379     12     136     262
Pretax, pre-provision earnings (non-GAAP1)   $ 45,261   $ 13,385   $ 33,315   $ 38,047   $ 37,263

Pretax, pre-provision earnings is a non-GAAP measure and is based on adjusting income before income taxes and to exclude provision for credit losses. We believe that pretax, pre-provision earnings is a useful tool to help evaluate the ability to provide for credit costs through operations and provides an additional basis to compare results between periods by isolating the impact of provision for credit losses, which can vary significantly between periods.

Tangible Common Equity (non-GAAP1)
    As of
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Common shareholders’ equity   $ 1,143,331   $ 1,191,766   $ 854,091   $ 844,236   $ 811,818
Less:                    
Intangible assets     74,402     80,754     38,063     41,747     45,431
Goodwill     118,345     118,345     36,253     34,149     34,149
Tangible common equity (non-GAAP1)   $ 950,584   $ 992,667   $ 779,775   $ 768,340   $ 732,238
Shares outstanding at end of period     20,193,639     20,165,171     15,045,941     15,028,524     15,028,524
Tangible book value per common share (non-GAAP1)   $ 47.07   $ 49.23   $ 51.83   $ 51.13   $ 48.72

In management’s view, tangible common equity measures are capital adequacy metrics that may be meaningful to the Company, as well as analysts and investors, in assessing the Company’s use of equity and in facilitating comparisons with peers. These non-GAAP measures are valuable indicators of a financial institution’s capital strength because they eliminate intangible assets from shareholders’ equity and retain the effect of accumulated other comprehensive income/(loss) in shareholders’ equity.

Tangible Common Assets (non-GAAP1)    
    As of
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Total assets   $ 11,034,393     $ 10,991,300     $ 7,927,711     $ 7,920,626     $ 7,889,037  
Less:                    
Intangible assets     74,402       80,754       38,063       41,747       45,431  
Goodwill     118,345       118,345       36,253       34,149       34,149  
Tangible assets (non-GAAP1)   $ 10,841,646     $ 10,792,201     $ 7,853,395     $ 7,844,730     $ 7,809,457  
                     
Tangible common equity / tangible assets (non-GAAP1)     8.77 %     9.20 %     9.93 %     9.79 %     9.38 %


Burke & Herbert Financial Services Corp.
Non-GAAP Reconciliations (unaudited)
(In thousands, except ratios and per share amounts)

In management’s view, tangible common assets measures complement tangible common equity measures and may be meaningful to the Company, as well as analysts and investors, in assessing balance sheet composition and leverage and in facilitating comparisons with peers. These non‑GAAP measures enhance transparency by eliminating intangible assets from total assets, thereby providing additional insight into the relationship between the Company’s tangible asset base and its tangible common equity.

Return and Adjusted Return on Average Tangible Common Equity and Average Assets (non-GAAP1)
    For the three months ended
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Average common shareholders’ equity   $ 1,193,226     $ 1,053,502     $ 861,274     $ 832,411     $ 782,577  
Average goodwill and other intangibles     (196,787 )     (159,202 )     (76,923 )     (79,338 )     (83,079 )
Average deferred tax liabilities on goodwill and other intangibles     18,204       19,635       8,602       9,382       9,787  
Average tangible common equity (non-GAAP1)   $ 1,014,643     $ 913,935     $ 792,953     $ 762,455     $ 709,285  
                     
Average total assets   $ 10,994,775     $ 10,010,483     $ 7,913,098     $ 7,979,528     $ 7,890,929  
Average goodwill and other intangibles     (196,787 )     (159,202 )     (76,923 )     (79,338 )     (83,079 )
Average deferred tax liabilities on goodwill and other intangibles     18,204       19,635       8,602       9,382       9,787  
Average tangible total assets (non-GAAP1)   $ 10,816,192     $ 9,870,916     $ 7,844,777     $ 7,909,572     $ 7,817,637  
                     
Net income applicable to common shareholders   $ 36,162     $ 9,257     $ 27,124     $ 30,019     $ 29,739  
                     
Operating net income applicable to common shareholders (non-GAAP1)   $ 43,382     $ 37,478     $ 28,238     $ 30,019     $ 29,739  
                     
Annualized return on average common equity     12.02 %     3.52 %     12.77 %     14.31 %     15.08 %
Annualized adjusted return on average common equity (non-GAAP1)     14.42       14.27       13.30       14.31       15.08  
Annualized return on average tangible common equity (non-GAAP1)     14.14       4.06       13.87       15.62       16.63  
Annualized adjusted return on average tangible common equity (non-GAAP1)     16.96       16.45       14.44       15.62       16.63  
Annualized return on average assets     1.30       0.37       1.39       1.49       1.50  
Annualized adjusted return on average assets (non-GAAP1)     1.57       1.50       1.45       1.49       1.50  

In management’s view, adjusted return on average common equity, return on average tangible common equity, adjusted return on average tangible common equity, and adjusted return on average assets are performance metrics that may be meaningful to the Company, as well as analysts and investors, in evaluating the Company’s profitability and efficiency in deploying capital and assets and in facilitating comparisons with peers. These non‑GAAP measures provide additional insight into the Company’s underlying operating performance by focusing on returns generated from common equity, tangible common equity, and total assets, as applicable.

The adjusted measures exclude the after‑tax effect of one‑time merger‑related expenses, which management believes enhances period‑to‑period comparability and provides a more representative view of the Company’s ongoing earnings performance. Return on average tangible common equity measures further isolate performance attributable to tangible capital by excluding the impact of intangible assets, while return on average assets reflects the Company’s effectiveness in generating earnings from its overall asset base. Management believes these measures, when considered together and alongside GAAP results, provide useful supplemental information for assessing profitability, capital efficiency, and operating trends.

Net Interest Margin & Taxable-Equivalent Net Interest Income (non-GAAP1)
    For the three months ended
    September 30   June 30   March 31   December 31   September 30
    2026   2026   2026   2025   2025
Net interest income   $ 105,016     $ 93,042     $ 71,843     $ 74,922     $ 73,770  
Taxable-equivalent adjustments     2,227       2,036       1,628       1,420       1,305  
Net interest income (Fully Taxable-Equivalent – FTE)   $ 107,243     $ 95,078     $ 73,471     $ 76,342     $ 75,075  
                     
Average interest-earning assets   $ 10,094,844     $ 9,198,632     $ 7,279,297     $ 7,363,743     $ 7,308,536  
Net interest margin (non-GAAP1)     4.21 %     4.15 %     4.09 %     4.11 %     4.08 %

The interest income earned on certain earning assets is completely or partially exempt from federal income tax. As such, these tax-exempt instruments typically yield lower returns than taxable investments. To provide more meaningful comparisons of net interest income, we use net interest income on a fully taxable-equivalent (FTE) basis by increasing the interest income earned on tax-exempt assets to make it fully equivalent to interest income earned on taxable investments. FTE net interest income is calculated by adding the tax benefit on certain financial interest earning assets, whose interest is tax-exempt, to total interest income then subtracting total interest expense. Management believes FTE net interest income is a standard practice in the banking industry, and when net interest income is adjusted on an FTE basis, yields on taxable, nontaxable, and partially taxable assets are comparable; however, the adjustment to an FTE basis has no impact on net income and this adjustment is not permitted under GAAP. FTE net interest income is only used for calculating FTE net interest margin, which is calculated by annualizing FTE net interest income and then dividing by the average earning assets. The tax rate used for this adjustment is 21%. Net interest income shown elsewhere in this presentation is GAAP net interest income.

______

1 Non-GAAP financial measures referenced in this release are used by management to measure performance in operating the business that management believes enhances investors’ ability to better understand the underlying business performance and trends related to core business activities. Reconciliations of non-GAAP operating measures to the most directly comparable GAAP financial measures are included in the non-GAAP reconciliation tables in this release. Non-GAAP measures should not be used as a substitute for the closest comparable GAAP measurements.
2 Ratios as of September 30, 2026, are estimated.
3 Includes Federal Home Loan Bank, Borrower-in-Custody (BIC), correspondent bank availability, and brokered deposit capacity.

4 Total delinquencies represent only accruing loans 30 days or more past due.
5 Includes non-accrual loans and loans 90 days past due and still accruing.

EL SEGUNDO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™ (the “Company”), today announced it will report financial results for its third quarter ended September 26, 2026 on Wednesday, November 4, 2026 after market close.

The Company will host a conference call to discuss these results at 5:00 p.m. Eastern, 2:00 p.m. Pacific. Investors interested in participating in the live call can dial 412-902-4255.

There will be a simultaneous, live webcast available on the Investor Relations section of the Company’s website at www.beyondmeat.com. The webcast will also be archived.

About Beyond Meat

Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™, is a plant protein company offering a portfolio of plant-based products made with non-GMO ingredients, no added hormones or antibiotics, and 0mg of cholesterol per serving. Founded in 2009, Beyond Meat’s core products are designed to have the same taste and texture as animal-based meat while being better for people and the planet. The company’s brand promise, Eat What You Love®, represents a strong belief that there is a better way to feed our future and that the positive choices we all make, no matter how small, can have a great impact on our personal health and the health of our planet. By shifting from animal-based protein to plant-based protein, we can positively impact four growing global issues: human health, climate change, constraints on natural resources and animal welfare. Visit www.BeyondMeat.com and follow @BeyondMeat on Facebook, Instagram, Threads and LinkedIn.

Contacts

Media:

Melanie Daifotis

Melanie.daifotis@beyondmeat.com

Investors:

Raphael Gross

beyondmeat@icrinc.com

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)

89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively

Proteinuria reductions sustained through 104 weeks following transition to every-other-week dosing; favorable safety profile

BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced final two-year results from the Phase 3 TELIGAN trial evaluating telitacicept in adults with IgA nephropathy (IgAN), conducted in China by its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331). TELIGAN met the Stage B primary endpoint, demonstrating a statistically significant difference in annualized estimated glomerular filtration rate (eGFR) slope through 104 weeks compared with placebo. The data were presented today in an oral presentation (TH-OR111) during the Featured High-Impact Clinical Trials plenary session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.

The 104-week findings build on the previously reported 39-week results, published in The New England Journal of Medicine in May 2026, and extend the evidence from proteinuria reduction to longer-term preservation of kidney function and reduced incidence of clinically relevant kidney disease progression events.

“At 104 weeks, TELIGAN demonstrated a substantial reduction in proteinuria and important evidence of durable kidney protection,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “An annualized eGFR slope approaching zero, lower rates of kidney function deterioration, and sustained proteinuria reductions following the transition to every-other-week dosing together reinforce the clinical potential of telitacicept. These findings add to the growing body of evidence supporting dual BAFF/APRIL inhibition as we continue to advance our global Phase 3 programs in myasthenia gravis and Sjögren’s disease.”

TELIGAN is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 318 adults with biopsy-confirmed IgAN receiving stable background supportive therapy. Patients were randomized 1:1 to telitacicept 240 mg or placebo. Treatment was administered subcutaneously once weekly through Week 39 (Stage A), followed by every-other-week dosing from Week 40 through Week 104 (Stage B). The Stage A primary endpoint assessed change in 24-hour urine protein-to-creatinine ratio (24h-UPCR) at Week 39; the Stage B primary endpoint assessed annualized eGFR slope through Week 104.

Key Findings from the Final 104-Week Analysis:

  • Kidney function preservation: Annualized eGFR slope through 104 weeks was -0.6 mL/min/1.73 m²/year (95% CI: -1.7 to 0.4) for telitacicept versus -5.7 mL/min/1.73 m²/year (95% CI: -7.0 to -4.5) for placebo, representing a between-group difference of 5.1 mL/min/1.73 m²/year (95% CI: 3.5 to 6.7; p<0.001).
  • Reduced kidney disease progression: Telitacicept was associated with an 89% lower risk of confirmed ≥30% eGFR decline (HR 0.11) and an 81% lower risk of confirmed ≥40% eGFR decline (HR 0.19) relative to placebo. No patient in the telitacicept group experienced a prespecified composite kidney failure endpoint event, compared with five in the placebo group, including two who required dialysis.
  • Durable proteinuria reduction: At Week 104, 24h-UPCR decreased 60.3% from baseline in the telitacicept group compared with a 0.9% increase in the placebo group, representing a reported placebo-adjusted reduction of 60.7%. At Week 104, 44.0% of telitacicept-treated patients achieved 24h-UPCR <0.5 g/g versus 8.2% in the placebo group. Reductions in proteinuria were maintained after the transition to every-other-week dosing.
  • Reduction in pathogenic IgA1: At Week 104, serum galactose-deficient IgA1 (Gd-IgA1) decreased 47.79% from baseline with telitacicept, compared with a 19.06% increase with placebo, consistent with the drug’s dual BAFF/APRIL mechanism.
  • Safety: Treatment-emergent adverse events occurred in 95.0% of telitacicept-treated patients and 89.3% of placebo-treated patients. Serious adverse events occurred in 8.2% versus 18.2%, respectively. Overall infections were reported in 67.3% of each group, and serious infections in 1.9% versus 4.4%. Injection-site reactions were more frequent with telitacicept (56.0% versus 18.9%), with most mild to moderate in severity.

In June 2026, telitacicept received conditional approval in China for the reduction of proteinuria in adults with primary IgAN at risk of disease progression. RemeGen is responsible for the development and commercialization of telitacicept in China, while Vor Bio holds exclusive rights to develop and commercialize telitacicept outside Greater China.

About IgA Nephropathy
IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and a leading cause of chronic kidney disease. It is characterized by deposition of IgA-containing immune complexes in the kidneys, resulting in inflammation, proteinuria, hematuria, and progressive loss of kidney function. Overproduction of Gd-IgA1 is a central driver of IgAN, and despite available therapies, patients remain at risk of progression to kidney failure.

About Telitacicept
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL – two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren’s disease (SjD).

Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “design,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “should,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the therapeutic and clinical potential of telitacicept, including its potential benefits in IgAN and other autoimmune diseases, its potential to preserve kidney function and slow disease progression, and the durability of its effects; the potential of dual BAFF/APRIL inhibition; the conditional approval of telitacicept in China and any conversion to full approval; Vor Bio’s development and commercialization plans, including potential regulatory approvals in the United States, Europe, and Japan; and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including that results from the TELIGAN trial, which RemeGen conducted solely in China, may not be predictive of results in other populations or in our ongoing or future clinical trials, and that the FDA and other regulators outside China may not accept data generated in China; that results of earlier clinical trials or analyses may not be predictive of future results, and that data presented at medical meetings may change following additional analysis or peer review; the risk of unexpected adverse events or safety findings; that conditional approvals in China may be withdrawn or not converted to full approval; our reliance on RemeGen, including for clinical data and the supply of telitacicept, and our ability to maintain our license with RemeGen; competition from other therapies, including other BAFF and/or APRIL inhibitors; that the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines; and possible limitations of financial and other resources. The clinical trial results described in this press release are based on information reported by RemeGen; Vor Bio has not independently verified these data. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

CONTACT: Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.